Welcome to our dedicated page for Cardinal Health SEC filings (Ticker: CAH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cardinal Health, Inc. (NYSE: CAH) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Cardinal Health is an Ohio corporation whose common shares trade on the New York Stock Exchange under the symbol CAH, as noted in multiple Form 8-K filings. These documents give investors detailed insight into the company’s financial condition, governance, capital structure, and material events.
Cardinal Health regularly files Form 8-K current reports to announce significant developments. Recent 8-K filings include disclosures about quarterly and annual financial results, updates to fiscal 2026 non-GAAP earnings per share outlook, entry into material definitive agreements such as credit facilities and receivables purchase amendments, public offerings of notes to help fund acquisitions like Solaris Health, and the completion of those offerings. Other 8-Ks document matters such as the 2025 Annual Meeting of Shareholders and voting results on director elections, say-on-pay, and auditor ratification.
The company’s definitive proxy statement on Schedule 14A (DEF 14A) offers extensive information on corporate governance, Board composition, executive compensation, and shareholder voting items. Cardinal Health’s proxy materials describe its strategic priorities, fiscal performance highlights, Board skills and refreshment, and engagement with shareholders.
Through Stock Titan, users can review Cardinal Health’s periodic and current reports and use AI-powered tools to summarize key points from lengthy filings. These tools help explain complex sections, highlight items such as non-GAAP metrics definitions, capital markets transactions, and credit agreements, and make it easier to track themes like Specialty growth, distribution network investments, and capital allocation. The filings page also surfaces relevant exhibits, including indentures, underwriting agreements, and amendments to financing arrangements, giving a structured view of Cardinal Health’s obligations and governance framework.
Cardinal Health (CAH) reported strong first‑quarter results for the period ended September 30, 2025. Revenue rose 22% to $64.0 billion, driven by branded and specialty pharmaceutical sales. GAAP operating earnings increased 18% to $668 million, while non‑GAAP operating earnings grew 37% to $857 million.
GAAP diluted EPS was $1.88 (up 11%) and non‑GAAP diluted EPS was $2.55 (up 36%), reflecting contributions from recently acquired MSO platforms and Advanced Diabetes Supply. Segment profit improved across the board: Pharma up 26% to $667 million, Global Medical up to $46 million, and Other up 60% to $166 million. GLP‑1 demand boosted sales but had limited profit impact due to mix.
Liquidity strengthened with $4.6 billion in cash and $973 million provided by operations, including $403 million in opioid‑related payments. The company issued $1.0 billion of new notes (4.5% due 2030; 5.15% due 2035), repaid $500 million of 2025 notes, and executed a $375 million accelerated share repurchase. CAH announced a definitive agreement to acquire Solaris Health for approximately $1.9 billion in cash plus an estimated $500 million in Specialty Alliance units, to be reported within the Pharma segment upon closing.
Cardinal Health, Inc. filed a current report to note that it has released financial results for the quarter ended September 30, 2025. The company issued a news release, which is furnished as Exhibit 99.1, summarizing its first-quarter performance.
The report also explains that the Chief Executive Officer and Chief Financial Officer will host a webcast at 8:30 a.m. Eastern time on October 30, 2025 to discuss the quarterly results and the outlook for the fiscal year ending June 30, 2026. A slide presentation and an audio replay of the webcast will be available on the Investors page of Cardinal Health’s website.
BlackRock Portfolio Management LLC filed a Schedule 13G reporting beneficial ownership of 11,947,456 shares (5.0%) of Cardinal Health, Inc. common stock. The firm reports sole voting power over 10,919,560 shares and sole dispositive power over 11,947,456 shares as of the event date.
The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing control. It also notes that various underlying persons have rights to dividends or sale proceeds, and no single person exceeds five percent of the outstanding common shares.
Cardinal Health, Inc. entered into a new 364-day credit agreement on October 7, 2025 with Bank of America, N.A. as administrative agent and a syndicate of lenders. The facility provides access to up to $1.0 billion of revolving credit through October 6, 2026 and replaces a similar 364-day agreement that expired from October 2024.
At the termination date, Cardinal Health may, subject to conditions in the agreement, convert any outstanding borrowings into non-revolving term loans that must be repaid one year later. The agreement includes customary representations, covenants and events of default, including a financial covenant requiring a consolidated net leverage ratio not greater than 3.75 to 1.00 as of the last day of any fiscal quarter.
The revolving credit facility may be used for general corporate purposes and backs the company’s commercial paper program. Participating financial institutions and their affiliates have previously provided, and may continue to provide, various banking and financial services to Cardinal Health for customary fees.
Cardinal Health, Inc. reported that several of its receivables financing subsidiaries and major banking partners entered into a First Amendment to an existing Fifth Amended and Restated Receivables Purchase Agreement originally dated September 1, 2023. The principal change is an extension of the term of this receivables financing facility to September 28, 2028, helping maintain access to funding backed by customer receivables.
Key counterparties include Wells Fargo, Liberty Street Funding, The Bank of Nova Scotia, PNC Bank, Bank of America, Victory Receivables Corporation and MUFG Bank. These institutions or their affiliates also provide other services to Cardinal Health, such as acting as dealers under its commercial paper program and participating in its
Cardinal Health's proxy highlights strong fiscal 2025 operating and governance outcomes. GAAP diluted EPS was $6.45 (prior year included a $617 million after-tax goodwill impairment of $2.50 per share). Non-GAAP diluted EPS was $8.24, a 9% increase year-over-year. The company generated $2.4 billion in operating cash flow, returned over $1.2 billion to shareholders ($750 million in repurchases and $494 million in dividends), invested $547 million in the business, and deployed $5.3 billion on acquisitions including ION, GI Alliance and Advanced Diabetes Supply Group. Performance share units for the 2023–2025 cycle settled at 212% of target after a 20% TSR modifier; three‑year TSR was 235.5% vs. 9.4% for the S&P 500 Health Care Index. Governance disclosures detail an independent, non-executive chairman, recent director additions (Messrs. Musslewhite and Ramakrishna), board refreshment practices, and executive compensation governance, including a disclosed CEO-to-median pay ratio of 261:1.
Cardinal Health, Inc. filed an 8-K reporting execution of a Third Supplemental Indenture dated August 27, 2025, with The Bank of New York Mellon Trust Company, N.A., as trustee, and included forms of two note series: 4.500% Notes due 2030 and 5.150% Notes due 2035. The filing incorporates the original Indenture dated June 2, 2008, and includes legal opinions and consents from Cardinal Health's General Counsel and White & Case LLP, plus an embedded Inline XBRL cover page.
The disclosure documents appear to support issuance or amendment of long-term debt instruments by the company and provide legal and trustee documentation required for such securities. The filing is signed by Aaron E. Alt, Chief Financial Officer.
Cardinal Health (CAH) Form 144 notice reports a proposed sale of 21,367 common shares through Merrill Lynch on 08/20/2025 with an aggregate market value of $3,216,330.00. The filing shows the shares were acquired on 08/15/2025 from Cardinal Health, Inc. as 13,088 shares from performance stock vesting and 8,279 shares from restricted stock vesting. No securities were reported sold by the same person in the past three months. The document includes the required representation that the seller is not aware of undisclosed material adverse information and references potential Rule 10b5-1 plan considerations.
Insider sale by Cardinal Health officer: The Form 4 shows Deborah Weitzman, identified as an officer (CEO, PSS Segment), sold 21,367 common shares on 08/20/2025 at a weighted average price of $150.53 per share (sales ranged $150.22 to $151.00). After the reported dispositions she beneficially owned 53,428 shares. The filing notes the weighted-average price and offers to provide detailed per-trade quantities and prices on request. No derivative transactions or additional acquisitions are reported in this Form 4.
Insider transactions reported for Cardinal Health, Inc. (CAH). The Form 4 shows Jason M. Hollar, listed as Chief Executive Officer and an officer reporting person, sold common shares on 08/20/2025 in two separate sets of transactions. The first sale disposed of 12,944 shares at a weighted average price of $149.40, leaving 222,957 shares beneficially owned. The second sale disposed of 22,957 shares at a weighted average price of $150.40, leaving 200,000 shares beneficially owned following that reported transaction.
The filings note the prices are weighted averages from multiple trades within specified ranges and state the reporting person will provide further breakdowns on request. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
FAQ
What is the current stock price of Cardinal Health (CAH)?
What is the market cap of Cardinal Health (CAH)?
